Rchr
J-GLOBAL ID:201901000250746275   Update date: Jun. 04, 2020

Kubo Toshio

Kubo Toshio
Affiliation and department:
Research field  (1): Tumor biology
Papers (56):
  • Makimoto G, Ohashi K, Tomida S, Nishii K, Matsubara T, Kayatani H, Higo H, Ninomiya K, Sato A, Watanabe H, Kano H, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Toyooka S, Takata M, Maeda Y, Kiura K. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019. 14. 11. 2009-2018
  • Makimoto G, Hotta K, Oze I, Ninomiya K, Nakanishi M, Hara N, Kano H, Watanabe H, Hata Y, Nishii K, Nakasuka T, Itano J, Ninomiya T, Kubo T, Ohashi K, Ichihara E, Minami D, Sato A, Tabata M, Maeda Y, Kiura K. Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta oncologica (Stockholm, Sweden). 2019. 1-5
  • Nishii K, Hotta K, Ninomiya K, Kato Y, Ichihara E, Ohashi K, Ninomiya T, Kubo T, Rai K, Tabata M, Maeda Y, Kiura K. Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory investigation. 2019. 57. 5. 460-465
  • Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K. A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement. Asia-Pacific journal of clinical oncology. 2019. 15. 4. 250-256
  • Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, Ochi N, Ninomiya T, Harada D, Yasugi M, Ichihara E, Ohashi K, Fujiwara K, Hotta K, Tabata M, Maeda Y, Kiura K. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Japanese journal of clinical oncology. 2019. 49. 8. 762-765
more...
Lectures and oral presentations  (3):
  • hase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
    (ESMO Asia Annual Meeting 2019)
  • Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients.
    (ESMO Annual Meeting 2018)
  • Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors
    (ASCO Annual Meeting 2018)
Education (2):
  • 2007 - 2013 Okayama University Graduate School of Medicine , Dentistry and Pharmaceutical Sciences
  • 1996 - 2002 Okayama University Medical School Faculty of Medicine
Work history (1):
  • 2013/12 - 現在 Okayama University Hospital Assistant Professor
Association Membership(s) (9):
American Society of Clinical Oncology ,  American Association for Cancer Research ,  JAPAN SOCIETY FOR PALLIATIVE MEDICINE ,  JAPAN SOCIETY OF CLINICAL ONCOLOGY ,  JAPAN SOCIETY OF MEDICAL ONCOLOGY ,  THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY ,  THE JAPAN LUNG CANCER SOCIETY ,  THE JAPANESE RESPIRATORY SOCIETY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page